A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer

Cancer
Daniel Y C HengChristian Kollmannsberger

Abstract

Sunitinib has replaced interferon (IFN) as a first-line standard of care in the treatment of metastatic renal cell carcinoma (RCC). This study aimed to determine overall survival and to confirm effectiveness in a population that includes poor prognosis patients. Data were collected on all patients identified by the BC Cancer Registry with metastatic RCC who were treated with IFN or sunitinib. The IFN group consisted of patients who received IFN between January 2000 and October 2005, and the sunitinib group included patients treated with first-line sunitinib from October 2005 to September 2007. There were 131 and 69 patients in the IFN and sunitinib groups, respectively. The median follow-up of those still alive was 12.6 months. The median age (62 vs 63 years; P = .41), Memorial Sloan Kettering Cancer Center (MSKCC) prognostic criteria (poor in 19% vs 30%; P = .41), and proportion with >1 metastasis (53% vs 62%; P = .21) were similar between the IFN and sunitinib groups, respectively. The median survival of the IFN and sunitinib groups was 8.7 and 17.3 months, respectively (log-rank P = .004). The median survival of patients with favorable, intermediate, and poor MSKCC prognostic profiles in the IFN group was 22.9, 8.7, and 4.1 ...Continue Reading

References

Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Aug 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YangSteven A Rosenberg
Dec 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David F McDermottMichael B Atkins
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tarek M MekhailRonald Bukowski
May 10, 2005·Diagnostic Cytopathology·Maria Sironi, Gianni Tunesi
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurie H SehnJoseph M Connors
Dec 13, 2005·The New England Journal of Medicine·Herbert T Cohen, Francis J McGovern
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
May 12, 2007·European Urology·Paul C M S Verhagen
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Sep 18, 2007·The Journal of Urology·Robert J MotzerGeorge Wilding
Oct 31, 2007·Nature Clinical Practice. Rheumatology·Robert Landewé, Désirée van der Heijde

❮ Previous
Next ❯

Citations

Nov 8, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D Y HengT K Choueiri
Jan 1, 2010·Therapeutic Advances in Medical Oncology·Daniel Y C HengKim N Chi
Jun 11, 2009·Current Opinion in Supportive and Palliative Care·Denis Soulières
Aug 6, 2013·Current Opinion in Supportive and Palliative Care·Denis Soulières
Feb 9, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A TunioM Rafi
Nov 30, 2010·Expert Review of Anticancer Therapy·Filippo SpreaficoLuigi Piva
Nov 5, 2015·Expert Review of Anticancer Therapy·Andrea CoinuSandro Barni
Jul 7, 2015·International Journal of Urology : Official Journal of the Japanese Urological Association·Nobuo Shinohara, Takashige Abe
Feb 19, 2014·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Juan Antonio CruzadoJaime Feliu
Apr 5, 2013·Therapeutic Advances in Urology·Maxine SunPierre I Karakiewicz
Jan 6, 2018·International Journal of Molecular Sciences·Inamul HaqueSushanta K Banerjee
Apr 20, 2010·Asia-Pacific Journal of Clinical Oncology·Thean Hsiang TanDesmond Yip
Feb 23, 2020·Health Economics·Warren StevensKrishnan Ramaswamy
May 30, 2012·International Journal of Oncology·John Shyi Peng YuenHung Huynh
Jun 5, 2020·OncoTargets and Therapy·Abhay SinghIgor Puzanov
Nov 10, 2009·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Georgios S Papaetis, Kostas N Syrigos
Aug 13, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Nathalie Theou-AntonEric Raymond
Jul 25, 2015·BJU International·Daphne DayBen Tran
May 2, 2018·Tumori·Jeffrey Graham, Daniel Yc Heng

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.